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Around the turn of the century, the
German bacteriologist Paul Ehrlich pre-
dicted that drugs would be invented that
would perform like "magic bullets"-locat-
ing and destroying diseased tissue, without
harming healthy tissue. The well-aimed
drugs that Ehrlich imagined would provide
unheard-of effectiveness with virtually no
side effects. Unfortunately, such drugs
remained largely in Ehrlich's fantasies until
last year when modern medical gunslingers
developed the equivalent of a magic bul-
let-drugs incorporated into fats.
The advent of pharmaceuticals pack-
aged in fats was in the early 1960s, when
Alec D. Bangham, then head of the bio-
physics unit at the Institute of Animal
Physiology in Babraham, England, discov-
ered that mixing phospholipids with water
produces microscopic bubbles, ranging
from 0.25 micrometers (pm) to more than
20 pm across. These bubbles, called lipo-
somes, consist ofa bilayer oflipids that sur-
rounds a watery interior. Almost immedi-
ately, liposomes appeared promising as
drug-delivery devices because ofthree char-
acteristics. First, liposomes can carry water-
soluble drugs in their hollow center or fat-
soluble drugs in their lipid bilayer. Second,
the lipids in liposomes also serve as build-
ing blocks for cells in our bodies, suggest-
ing that liposomes should be safe for med-
ical use. Third, it appeared possible to
design liposomes that would accumulate in
specific tissues, where the encapsulated
drugwould leak out slowly.
"In the nearly 30 years since their
rather serendipitous discovery," Bangham
wrote in the 15 December 1992 issue of
Hospital Practice, "liposomes have demon-
strated a versatility and utility that have
exceeded expectations. . A stream of
pharmaceutical agents may be expected in
the years to come." Several new drugs now
promise to swell that lipid-based stream.
Fighting Fungus
Some fungus-fighting pharmaceutical ben-
efits arise from how our body handles lipo-
somes. When a liposome enters the body,
plasma proteins bind to it. In some cases,
the proteins then tag the structure for
destruction by the immune system, partic-
ularly by macrophages located largely in
the liver and spleen. When macrophages
gobble up the intruding liposomes, the
drug is released into the macrophages,
which are common hiding places for sys-
temic fungal infections. This process
spurred investigators to explore liposome-
based antifungals.
Physicians need new tools for fighting
fungal infections. According to Mitchell
Cohen, director ofthe Division ofBacterial
and Mycotic Diseases at the Centers for
Disease Control, "Many fungal diseases are
becoming more common, primarily
because of an increasing frequency of sus-
ceptible hosts. We have more patients with
diseases that suppress the immune system,
such as malignancies and HIV infections.
In addition, patients are becoming more
susceptible because of intentional treat-
ments, such as organ transplantation,
chemotherapy, or high-dose steroids. All of
these conditions and treatments make peo-
ple susceptible to a variety offungal agents,
many ofwhich are ubiquitous in the envi-
ronment. Some of these agents, such as
aspergillosis, are very, very difficult to
treat." Aspergillosis, which is caused by a
mold, is often devastating to people who
are immunocompromised.
If a patient contracts a systemic fungal
infection, a physician may prescribe
amphotericin B-a powerful, broad-spec-
trum antifungal. Unfortunately, a dose
large enough to kill the fungus might also
kill the patient, because the drug can dam-
age a patient's bone marrow, central ner-
vous system, and kidneys. Some of these
side effects can be reduced by enveloping g
amphotericin B in a liposome, or by sim- -
ply mixing the drugwith lipids.
Last November, the FDA approved
treating some cases ofaspergillosis with an
antifungal mixed with lipids. The
Liposome Company in Princeton, New
Jersey, produces the antifungal, Abelcet,
which consists of amphotericin B mixed
with two phospholipids. A precise ratio of
these ingredients generates structures that
resemble ribbons, which, in cross section,
resemble a daisy with petals composed of
alternating phospholipids and ampho-
tericin B.
According to Thomas Walsh, head of
the mycology unit in the Pediatric Branch
of the National Cancer Institute, "Abelcet,
also known as amphotericin B lipid com-
plex [ABLC], is indicated for the treatment
of children and adults who have invasive
aspergillosis and are refractory to or intoler-
ant of conventional amphotericin B.
Abelcet has been shown in open-label and
controlled trials to be significantly less
nephrotoxic than conventional ampho-
tericin B, while retaining antifungal activity
that is at least equivalent to that ofthe par-
Antifungal flower? The daisylike structure of
amphotericin B mixed with two phospholipids
helpsthe new drug target aspergillosis.
Volume 104, Number4, April 1996 * EnvironmentalHealth Perspectives 390Innovations * Fat Pharms
ent compound." Walsh added, "The cost of
Abelcet, which is higher than that of con-
ventional amphotericin B, must be balanced
against the cost ofthe dose-limiting nephro-
toxicity of amphotericin B. Prudent use of
Abelcet in appropriate patients will also
contribute to controlling institutional
costs." In conclusion, Walsh called Abelcet
"an important and long-awaited addition to
our therapeutic armamentarium against
invasive fungal infections."
At least three other lipid-based antifun-
gals should reach the U.S. market over the
next couple of years. Sequus Pharma-
ceuticals, Inc. in Menlo Park, California, is
awaiting FDA approval for Amphotec, a
nonliposome mixture of amphotericin B
and lipids. Likewise, NeXstar Pharma-
ceuticals, Inc. in Boulder, Colorado, hopes
to bring AmBisome-a liposomal form of
amphotericin B-to the U.S. market.
Finally, Aronex Pharmaceuticals, Inc. in
The Woodlands, Texas, is performing clin-
ical tests on NystatinLFa liposomal form
of the antifungal nystatin. Nystatin alone
proves too toxic for intravenous use, but
the liposomal form can be injected and
appears effective in fighting fungal infec-
tions.
TargetingTumors
Although being consumed by macrophages
may improve the effectiveness of some
lipid-based drugs, avoiding that destruc-
tion presents other pharmaceutical oppor-
tunities. In fact, liposomes that escape
detection by macrophages can end up in
cancerous tumors. Loading such tumor-
targeting liposomes with anticancer drugs
produces a concentrated attack on cancer,
while sparing healthy tissue from the side
effects of traditional chemotherapy.
Liposomes are now engineered to avoid
detection by macrophages, largely by alter-
ing the liposome's surface molecules.
Liposomes must also be designed
appropriately to concentrate in tumors.
These microscopic bubbles must be manu-
factured to a precise size and must possess
long-term stability in blood for a cancerous
tumor to reel in the drug-filled liposomes.
A growing tumor releases growth factors
that stimulate blood-vessel formation,
(angiogenesis). These tumor-triggered ves-
sels include gaps in their walls and even
open-ended tubes in some cases. So a lipo-
some ofthe right size is contained in regu-
lar blood vessels but slips through the gaps
in tumor-feeding vessels, concentrating
drug-filled liposomes within the tumor.
In 1989, investigators at Sequus dis-
covered that adding a polyethylene glycol
coating to a liposome gives it a long, stable
life in circulation. Frank Martin, vice presi-
dent and chief scientific officer at Sequus,
said, "The fact that these liposomes circu-
late for so long means that they're passing
through a tumor's . . capillary bed many
times. Over a period of days after injec-
tion, the liposomes move from the lumen
of a tumor blood vessel through the gaps
and into the tumor, where they get stuck.
The liposomes sit there and, as my mother
would say, 'stew in their own juice.'
Eventually, the liposomes break down over
a period of days to weeks and the drug
comes out. So it's like delivering a little
time-released pill to the tumor."
Liposome-based chemotherapy appears
particularly suited to Kaposi's sarcoma, a
form of skin cancer that appears most
often in HIV-infected men. This cancer
generates reddish or purplish skin lesions,
or tumors, which are colored by red blood
cells that escape defective capillaries and
leave deposits of hemoglobin. At an
advanced stage, conventional treatment for
this cancer involves a combination of the
drugs adriamycin, bleomycin, and vin-
cristine (ABV). Unfortunately, this trio of
drugs produces serious side effects, includ-
ing damage to a patient's heart and bone
marrow. These side effects and the fact
that Kaposi's sarcoma produces a highly
vascular tumor encouraged trials with lipo-
some-based chemotherapy.
Kaposi's sarcoma can be treated with
Sequus's Doxil, the first liposomal drug
approved by the FDA. Doxil consists of
doxorubicin-a conventional anticancer
drug-encapsulated in liposomes that are
coated with polyethylene glycol. The poly-
mer coating gives this liposomal drug a cir-
culating half-life (the time it takes for half
the dose to be eliminated or disintegrated)
of 50 hours compared with a 10-minute
half-life for doxorubicin alone. In a
Sequus-sponsored study of
therapy for Kaposi's sarcoma,
Doxil produced a clinical
response in 43.2% of the
patients, conipared with ABV's
24.5% response rate. More-
over, only 32.3% of the
patients using Doxil could not
complete the study because of
adverse effects, whereas 65.6%
of the patients receiving ABV
could not complete the treat-
ment. In other words, Doxil
proved more effective and less
toxic in comparison with ABV.
Doxil is now being tested
against breast, ovarian, and
prostate cancers.
Donald W. Northfelt, a Magic bull
hematologist and oncologist dermal les
with the Pacific Oaks Medical anticancer
Group who served as a principal investiga-
tor in studies of Doxil as a treatment for
Kaposi's sarcoma, said, "It was especially
gratifying that patients who'd received reg-
ular doxorubicin as part of their previous
treatment for Kaposi's sarcoma, but were
not getting the response that they needed,
would start responding when switched to
Doxil." When asked about the overall
value of liposomal chemotherapy, he said,
"I think we're just on the verge of a new
era in chemotherapy with the use of this
technology."
The added benefits ofDoxil do impose
a cost, however. According to Tony
Goosmann, director of marketing at
Sequus, Doxil costs $485 per 20 mil-
ligrams. When being used against Kaposi's
sarcoma, that unit price translates to about
$1,000 per treatment cycle, with a patient
usually receiving a treatment every three
weeks. Goosmann says that, in comparison
to using ABV, Doxil costs roughly twice as
much.
Several other companies hope to market
additional liposomal forms of chemothera-
py. For instance, NeXstar is awaiting FDA
approval for a liposomal drug, DaunoXome,
which delivers a conventional anticancer
drug called daunorubicin. DaunoXome will
also be used against Kaposi's sarcoma. In
addition, The Liposome Company-in a
joint effort with Pfizer, Inc.-is producing
another liposomal form of doxorubicin
called TLC D-99, which remains under
development. Results from clinical trials
indicate that this drug may battle metastat-
ic breast cancer, particularly when com-
bined with other forms of chemotherapy.
Finally, Aronex's TretinoinLF, a liposomal
form of all-trans-retinoic acid (vitamin A),
is being tested against Kaposi's sarcoma and
leukemia.
llets. Liposomes concentrate in Kaposi's sarcoma-like
sions in mice, suggesting they may be used to carry
drugs directly to tumors.
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Expanding Applications
Today's world of lipid-associated pharma-
ceuticals revolves largely around antifungal
and chemotherapeutic drugs for two rea-
sons. First, many other types ofdrugs can-
not be combined with liposomes. Second,
other drugs may not benefit from being
delivered with lipids, or going where lipids
take them. Despite these obstacles,
researchers expect to see liposomal drugs
approved for other diseases. For example,
The Liposome Company's TLC C-53, a
liposomal form of prostaglandin E1, is
being developed to treat a variety ofcondi-
tions, including adult respiratory distress
syndrome and heart attacks.
Blood bubbles. Liposomes filled with hemoglobin may
vide an alternative to natural red blood cells.
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Moreover, the natural circulation of
liposomes in a human body suggests other
potential applications. Instead of fighting
cancer cells in a tumor, for instance, lipo-
somes might be formulated with drugs that
interfere with angiogenesis, thereby starv-
ing a growing tumor. And,
because liposomes collect at
I sites of inflammation and
Z wounds, they might be
filled with anti-inflammato-
ry or wound-healing drugs.
Projects are underway in
these areas.
Nevertheless, liposomes
are not limited to delivering
drugs. For example, lipo-
somes may be used to carry
oxygen. Alan Rudolph, a
program manager at the
Naval Research Laboratory's
_gS1 Center for Biomolecular
Science and Engineering,
some day pro- and his colleagues packlipo-
somes with hemoglobin,
and the combined structure performs much
like a natural red blood cell, carryingoxygen.
Rudolph hopes that these "artificial red
blood cells" will be employed when physi-
cians need units of packed red blood cells.
So far, this product has performed well in
the early stages of animal testing, but it
remains to be seen how a human will react
to the high doses of liposomes that are
involved in this application. Rudolph added
that some modifications might be required
to make the product cost-competitive, but it
may provide a safe red-cell substitute-one
with no riskofviral or antigen transmission.
Although fat is often considered a pub-
lic-health enemy, that characterization may
change as lipid-based pharmaceuticals
become more widely available. In the end,
Bangham's liposomal "stream of pharma-
ceutical agents" may overrun its banks,
generating a flood of tiny fat bubbles that
make us well.
Mike May
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